arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Alpha Teknova, Inc.

TKNO
$6.49 ▼ -0.03 (-0.46%) at close
Healthcare ·In Vitro & In Vivo Diagnostic Substances ·USIn Vitro & In Vivo Diagnostic Substances
26 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
28
Health
Poor
Bearish
auto_awesome

Analytical Summary

Alpha Teknova, Inc. faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $347.9M
Dividend Yield
Revenue Growth 13.1%
Op. Margin -38.8%
ROIC -5.6%
FCF / Share $-0.07
Trailing P/E
Price / Book 5.4x
FCF Yield
Debt / Equity 0.20
info Valuation on last close. End-of-day price, Aug 7, 2026.

26-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$11.08M
↑ +13.1%
Net Income Profit after all expenses
$-4.55M
↑ +1.9%
Operating Margin Operating profit as % of sales
-38.8%
↑ +15.9% 6th
FCF / Share Free cash flow per share
$-0.07
↑ +17.2%
Long-Term Debt Long-term obligations
$13.17M
— +0.4%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
7
Returns
25
Financial Health
51
Cash Quality
43

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 7 years · 26 quarters